- Home
- DHAI vs CYCC Comparison
DHAI vs CYCC Comparison
Compare DHAI & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- CYCC
- Stock Information
- Founded
- DHAI 2007
- CYCC 1992
- Country
- DHAI United States
- CYCC Malaysia
- Employees
- DHAI N/A
- CYCC N/A
- Industry
- DHAI
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- CYCC Health Care
- Exchange
- DHAI NYSE
- CYCC Nasdaq
- Market Cap
- DHAI 49.1M
- CYCC 47.6M
- IPO Year
- DHAI N/A
- CYCC N/A
- Fundamental
- Price
- DHAI $0.17
- CYCC $0.23
- Analyst Decision
- DHAI
- CYCC Strong Buy
- Analyst Count
- DHAI 0
- CYCC 1
- Target Price
- DHAI N/A
- CYCC $11.00
- AVG Volume (30 Days)
- DHAI 1.0M
- CYCC 162.6K
- Earning Date
- DHAI 02-14-2025
- CYCC 05-13-2025
- Dividend Yield
- DHAI N/A
- CYCC N/A
- EPS Growth
- DHAI N/A
- CYCC N/A
- EPS
- DHAI N/A
- CYCC N/A
- Revenue
- DHAI $69,573,000.00
- CYCC $43,000.00
- Revenue This Year
- DHAI N/A
- CYCC $137.21
- Revenue Next Year
- DHAI N/A
- CYCC N/A
- P/E Ratio
- DHAI N/A
- CYCC N/A
- Revenue Growth
- DHAI 5.40
- CYCC N/A
- 52 Week Low
- DHAI $0.12
- CYCC $0.17
- 52 Week High
- DHAI $3.67
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- DHAI 35.50
- CYCC 43.58
- Support Level
- DHAI $0.14
- CYCC $0.17
- Resistance Level
- DHAI $0.20
- CYCC $0.32
- Average True Range (ATR)
- DHAI 0.04
- CYCC 0.02
- MACD
- DHAI 0.01
- CYCC 0.00
- Stochastic Oscillator
- DHAI 36.22
- CYCC 75.25
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.